JP2015524469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524469A5 JP2015524469A5 JP2015526567A JP2015526567A JP2015524469A5 JP 2015524469 A5 JP2015524469 A5 JP 2015524469A5 JP 2015526567 A JP2015526567 A JP 2015526567A JP 2015526567 A JP2015526567 A JP 2015526567A JP 2015524469 A5 JP2015524469 A5 JP 2015524469A5
- Authority
- JP
- Japan
- Prior art keywords
- acetoxy
- propoxy
- diphenyl
- piperidinium
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- -1 piperidinium halide Chemical class 0.000 claims 5
- HBPSMMXRESDUSG-UHFFFAOYSA-N piperidine;hydroiodide Chemical compound I.C1CCNCC1 HBPSMMXRESDUSG-UHFFFAOYSA-N 0.000 claims 4
- DCECJWAHKJWZAX-UHFFFAOYSA-N [I-].C(C)(=O)O[NH+]1CCCCC1 Chemical compound [I-].C(C)(=O)O[NH+]1CCCCC1 DCECJWAHKJWZAX-UHFFFAOYSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681415P | 2012-08-09 | 2012-08-09 | |
| US61/681,415 | 2012-08-09 | ||
| PCT/US2013/052626 WO2014025569A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524469A JP2015524469A (ja) | 2015-08-24 |
| JP2015524469A5 true JP2015524469A5 (enExample) | 2016-09-15 |
| JP6345665B2 JP6345665B2 (ja) | 2018-06-20 |
Family
ID=50068488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526567A Expired - Fee Related JP6345665B2 (ja) | 2012-08-09 | 2013-07-30 | ピペリジニウム第四級塩類 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9896416B2 (enExample) |
| EP (1) | EP2882711B1 (enExample) |
| JP (1) | JP6345665B2 (enExample) |
| KR (2) | KR102240999B1 (enExample) |
| CN (2) | CN104603108A (enExample) |
| AU (1) | AU2013300009B2 (enExample) |
| BR (1) | BR112015002832B1 (enExample) |
| CA (1) | CA2881182C (enExample) |
| EA (1) | EA029678B9 (enExample) |
| HK (1) | HK1211572A1 (enExample) |
| IL (1) | IL236996A0 (enExample) |
| IN (1) | IN2015DN01018A (enExample) |
| MX (1) | MX356386B (enExample) |
| WO (1) | WO2014025569A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978201A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
| WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| JP7365613B2 (ja) | 2019-08-22 | 2023-10-20 | オフィノ， エルエルシー | マルチアクセスに対するポリシー制御 |
| CN117018194A (zh) * | 2023-07-26 | 2023-11-10 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD106643A1 (enExample) | 1973-07-12 | 1974-06-20 | ||
| CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
| DE10129832A1 (de) | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
| KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
| KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
| PT1713473E (pt) * | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| EP1921989A2 (en) * | 2005-08-12 | 2008-05-21 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Neuronal avalanche assay |
| CN1951938A (zh) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | 戊乙奎醚季铵盐及其衍生物 |
| SE0600876L (sv) | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| EP2013172A4 (en) | 2006-04-24 | 2010-08-04 | Astrazeneca Ab | NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE |
| CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| EP2470504B1 (en) * | 2010-03-15 | 2013-10-16 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
| CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
| WO2014039627A1 (en) * | 2012-09-05 | 2014-03-13 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
-
2013
- 2013-07-30 AU AU2013300009A patent/AU2013300009B2/en not_active Ceased
- 2013-07-30 CA CA2881182A patent/CA2881182C/en active Active
- 2013-07-30 EP EP13827594.6A patent/EP2882711B1/en active Active
- 2013-07-30 CN CN201380042085.3A patent/CN104603108A/zh active Pending
- 2013-07-30 IN IN1018DEN2015 patent/IN2015DN01018A/en unknown
- 2013-07-30 BR BR112015002832-2A patent/BR112015002832B1/pt not_active IP Right Cessation
- 2013-07-30 KR KR1020207005139A patent/KR102240999B1/ko not_active Expired - Fee Related
- 2013-07-30 KR KR20157006047A patent/KR20150040355A/ko not_active Ceased
- 2013-07-30 JP JP2015526567A patent/JP6345665B2/ja not_active Expired - Fee Related
- 2013-07-30 CN CN201810664740.3A patent/CN108658842A/zh active Pending
- 2013-07-30 HK HK15112219.3A patent/HK1211572A1/xx unknown
- 2013-07-30 WO PCT/US2013/052626 patent/WO2014025569A1/en not_active Ceased
- 2013-07-30 US US14/419,381 patent/US9896416B2/en active Active
- 2013-07-30 MX MX2015001769A patent/MX356386B/es active IP Right Grant
- 2013-07-30 EA EA201500209A patent/EA029678B9/ru unknown
-
2015
- 2015-01-29 IL IL236996A patent/IL236996A0/en unknown